赛诺医疗关联交易与业绩预增引关注

Core Viewpoint - Recent events involving Sino Medical, including related party transactions, new product approvals, share buybacks, and performance forecasts, have attracted market attention [1] Group 1: Related Party Transactions - The company held an extraordinary board meeting to review the proposal regarding the waiver of the preferential right to acquire shares in its subsidiary, which may involve changes in subsidiary equity [2] Group 2: Project Advancement - The company received a registration certificate from the National Medical Products Administration for a drug-eluting stent system, which is intended for the treatment of vascular stenosis in heart disease patients, potentially enriching the company's product portfolio [3] Group 3: Financial Movements - Since 2024, the company has been continuously repurchasing shares and announced a buyback plan of up to 300 million yuan in December 2025, with the founder also making multiple share purchases [4] Group 4: Performance Outlook - The company disclosed a performance forecast for 2025, expecting a year-on-year increase in net profit attributable to shareholders of 2767% to 3233%, primarily due to increased product sales and reduced expenses [5] Group 5: Stock and Fund Performance - The company's stock price increased by 2.12%, with a net inflow of 2.1817 million yuan in main funds, indicating high trading activity [6]